The next Nimbus? Head of billion-dollar drug program launches HotSpot with $45M A round
Remember that billion-dollar drug idea that got little Nimbus on Gilead’s radar back in 2016? Well, the folks behind that drug are building a whole platform on a similar concept. And they’re not just tackling NASH, but a whole lineup of previously undruggable targets.
The venture, called HotSpot Therapeutics, came out Tuesday with news that it’s being backed by Nimbus’ lead investor — Atlas Venture — in a $45 million Series A round co-led by Sofinnova.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.